Kailera Therapeutics (NASDAQ:KLRA) Reaches New 12-Month Low – What’s Next?

Posted by Geri Gentry on Sep 2nd, 2026

Kailera Therapeutics, Inc. (NASDAQ:KLRA – Get Free Report) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $15.63 and last traded at $15.71, with a volume of 168337 shares. The stock had previously closed at $16.21.

Analyst Ratings Changes

A number of brokerages recently commented on KLRA. Jefferies Financial Group assumed coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They set a “buy” rating and a $48.00 price objective for the company. TD Cowen started coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $57.00 target price on the stock. Evercore assumed coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set an “outperform” rating for the company. Weiss Ratings initiated coverage on shares of Kailera Therapeutics in a report on Friday, August 14th. They issued a “sell (d)” rating on the stock. Finally, Zacks Research upgraded shares of Kailera Therapeutics to a “hold” rating in a research report on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kailera Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $42.75.

Check Out Our Latest Research Report on KLRA

Kailera Therapeutics Price Performance

The firm has a market cap of $2.13 billion and a price-to-earnings ratio of -0.00. The company has a 50-day moving average of $18.84.

Kailera Therapeutics (NASDAQ:KLRA – Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.35). On average, equities analysts expect that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of KLRA. Wellington Management Group LLP bought a new stake in shares of Kailera Therapeutics during the second quarter valued at about $64,308,000. Atlas Venture Life Science Advisors LLC bought a new position in Kailera Therapeutics in the 2nd quarter valued at about $113,923,000. Frazier Life Sciences Management L.P. acquired a new position in Kailera Therapeutics during the 2nd quarter valued at about $24,233,000. Finally, California State Teachers Retirement System bought a new stake in shares of Kailera Therapeutics during the 2nd quarter worth about $309,000.

Kailera Therapeutics Company Profile

(Get Free Report)

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.